Citozar (cytarabine) powder for solution 1000 mg. №1 vial


Manufacturer: Italy



Achieving and maintaining remission in acute non-lymphoblastic leukemias in adults and children.

Treatment of other types of leukemia, such as acute lymphocytic leukemia, chronic myeloblastic leukemia (blast crisis).

Prevention or treatment of leukemic meningitis intrathecally, as monotherapy or in combination with other drugs (methotrexate, hydrocortisone).

Cytosar can be used as a monotherapy or in combination with other Antineoplastic agents; the best results are usually achieved with complex treatment. Remissions induced by Cytosar are short-term without further maintenance therapy.

Treatment of leukemia with a high risk of complications, refractory leukemia and relapse of acute leukemia, regardless of the concomitant use of anti-tumor chemotherapeutic agents with high doses of the drug.

As part of a combination therapy (LSA2L2) for the treatment of non-Hodgkin’s lymphomas in children.

Cytosar was experimentally used to treat various types of neoplasms. In General, a small number of patients with solid tumors had a positive response to treatment.